NO309032B1 - Nye tricykliske amider, fremgangsmÕter ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem - Google Patents
Nye tricykliske amider, fremgangsmÕter ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem Download PDFInfo
- Publication number
- NO309032B1 NO309032B1 NO961456A NO961456A NO309032B1 NO 309032 B1 NO309032 B1 NO 309032B1 NO 961456 A NO961456 A NO 961456A NO 961456 A NO961456 A NO 961456A NO 309032 B1 NO309032 B1 NO 309032B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- compounds
- alkyl
- give
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 69
- 238000000034 method Methods 0.000 title claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 150000001408 amides Chemical class 0.000 title abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 37
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 27
- 125000003118 aryl group Chemical group 0.000 claims abstract description 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 12
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 262
- 239000000203 mixture Substances 0.000 claims description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 37
- 239000000741 silica gel Substances 0.000 claims description 34
- 229910002027 silica gel Inorganic materials 0.000 claims description 34
- 238000000746 purification Methods 0.000 claims description 30
- 229910052727 yttrium Inorganic materials 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 238000004587 chromatography analysis Methods 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 239000003610 charcoal Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 230000001193 melatoninergic effect Effects 0.000 claims description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 10
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 238000005185 salting out Methods 0.000 claims description 9
- 150000008064 anhydrides Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- NSODBKSYAOTJPJ-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical group C1=CC(CC(NC(=O)C)C2)=C3C2=CC=CC3=C1 NSODBKSYAOTJPJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- ARDJQVYHKXUPRR-UHFFFAOYSA-N n-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical group C1=CC=C2CC(NC(C)=O)CC3=C2C1=CC=C3OC ARDJQVYHKXUPRR-UHFFFAOYSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 229910052705 radium Inorganic materials 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- OFAWPCDIYXXTFH-UHFFFAOYSA-N n-(4,9-dimethoxy-2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical group C1=CC(OC)=C2CC(NC(C)=O)CC3=C2C1=CC=C3OC OFAWPCDIYXXTFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000006168 tricyclic group Chemical group 0.000 claims description 2
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- -1 phenalen-2-yl Chemical group 0.000 abstract description 19
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 82
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 24
- 150000003254 radicals Chemical class 0.000 description 19
- 239000012429 reaction media Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 238000004809 thin layer chromatography Methods 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 238000013459 approach Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 101150065749 Churc1 gene Proteins 0.000 description 14
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 14
- 102100038239 Protein Churchill Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- 235000019341 magnesium sulphate Nutrition 0.000 description 14
- 229960003987 melatonin Drugs 0.000 description 14
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical class [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000033764 rhythmic process Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241001494479 Pecora Species 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 102000001419 Melatonin receptor Human genes 0.000 description 6
- 108050009605 Melatonin receptor Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000027288 circadian rhythm Effects 0.000 description 6
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- FJDDSMSDZHURBJ-XSBOKVBDSA-N n-[2-(2-iodanyl-5-methoxy-1h-indol-3-yl)ethyl]acetamide Chemical compound COC1=CC=C2NC([125I])=C(CCNC(C)=O)C2=C1 FJDDSMSDZHURBJ-XSBOKVBDSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 210000003574 melanophore Anatomy 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- LRONDFPQGQIHFW-UHFFFAOYSA-N n-(1-hydroxy-2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical compound C1=CC(C(C(NC(=O)C)C2)O)=C3C2=CC=CC3=C1 LRONDFPQGQIHFW-UHFFFAOYSA-N 0.000 description 3
- QSGLKTVBGKMMPD-UHFFFAOYSA-N n-(4,9-dimethoxy-3-oxo-1,2-dihydrophenalen-2-yl)acetamide Chemical compound C1=CC(OC)=C2C(=O)C(NC(C)=O)CC3=C2C1=CC=C3OC QSGLKTVBGKMMPD-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PPKHAIRFQKFMLE-UHFFFAOYSA-N 2,7-dimethoxynaphthalene Chemical compound C1=CC(OC)=CC2=CC(OC)=CC=C21 PPKHAIRFQKFMLE-UHFFFAOYSA-N 0.000 description 2
- PTTJQHKRNJYUGV-UHFFFAOYSA-N 2,7-dimethoxynaphthalene-1-carbaldehyde Chemical compound C1=CC(OC)=C(C=O)C2=CC(OC)=CC=C21 PTTJQHKRNJYUGV-UHFFFAOYSA-N 0.000 description 2
- XCXPYPHSALKFCI-UHFFFAOYSA-N 2-acetamido-3-(2-methoxynaphthalen-1-yl)propanoic acid Chemical compound C1=CC=CC2=C(CC(NC(C)=O)C(O)=O)C(OC)=CC=C21 XCXPYPHSALKFCI-UHFFFAOYSA-N 0.000 description 2
- RGIWZNSMSXQWLY-UHFFFAOYSA-N 2-acetamido-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CC=CC2=C1 RGIWZNSMSXQWLY-UHFFFAOYSA-N 0.000 description 2
- ZDPFZBDQGKUBLK-UHFFFAOYSA-N 4-[(2,7-dimethoxynaphthalen-1-yl)methyl]-2-methyl-4h-1,3-oxazol-5-one Chemical compound C12=CC(OC)=CC=C2C=CC(OC)=C1CC1N=C(C)OC1=O ZDPFZBDQGKUBLK-UHFFFAOYSA-N 0.000 description 2
- 208000027559 Appetite disease Diseases 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 230000020335 dealkylation Effects 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- JFJOMJMGBFBOEI-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)propanamide Chemical compound C1=CC(CC(NC(=O)CC)C2)=C3C2=CC=CC3=C1 JFJOMJMGBFBOEI-UHFFFAOYSA-N 0.000 description 2
- QSGJAWCSMSGFBG-UHFFFAOYSA-N n-(4-hydroxy-9-methoxy-3-oxo-1,2-dihydrophenalen-2-yl)acetamide Chemical compound C1=CC(O)=C2C(=O)C(NC(C)=O)CC3=C2C1=CC=C3OC QSGJAWCSMSGFBG-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000026234 pro-estrus Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UZGZPQGJNHDHKO-UHFFFAOYSA-N (1-methoxynaphthalen-2-yl)methanol Chemical compound C1=CC=C2C(OC)=C(CO)C=CC2=C1 UZGZPQGJNHDHKO-UHFFFAOYSA-N 0.000 description 1
- OLBXWIJEZKBUBV-UHFFFAOYSA-N (2,7-dimethoxynaphthalen-1-yl)methanol Chemical compound C1=CC(OC)=C(CO)C2=CC(OC)=CC=C21 OLBXWIJEZKBUBV-UHFFFAOYSA-N 0.000 description 1
- QUFXVYRFRKHGBW-UHFFFAOYSA-N (3-methoxynaphthalen-2-yl)methanol Chemical compound C1=CC=C2C=C(CO)C(OC)=CC2=C1 QUFXVYRFRKHGBW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CGSYKRJQLUCLOR-UHFFFAOYSA-N 1-(chloromethyl)-2-methoxynaphthalene Chemical compound C1=CC=CC2=C(CCl)C(OC)=CC=C21 CGSYKRJQLUCLOR-UHFFFAOYSA-N 0.000 description 1
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 1
- JQMPQZGIXRHPED-UHFFFAOYSA-N 1-butyl-3-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)urea Chemical compound C1=C(OC)C(CC(NC(=O)NCCCC)C2)=C3C2=CC=CC3=C1 JQMPQZGIXRHPED-UHFFFAOYSA-N 0.000 description 1
- QZKSMIXYUYTBSS-UHFFFAOYSA-N 1-ethyl-3-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)urea Chemical compound C1=C(OC)C(CC(NC(=O)NCC)C2)=C3C2=CC=CC3=C1 QZKSMIXYUYTBSS-UHFFFAOYSA-N 0.000 description 1
- LSPLSWXKCFUDCZ-UHFFFAOYSA-N 1-hexyl-3-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)urea Chemical compound C1=C(OC)C(CC(NC(=O)NCCCCCC)C2)=C3C2=CC=CC3=C1 LSPLSWXKCFUDCZ-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- PHRABVHYUHIYGY-UHFFFAOYSA-N 1-methylnaphthalene Chemical class C1=CC=C2C([CH2])=CC=CC2=C1 PHRABVHYUHIYGY-UHFFFAOYSA-N 0.000 description 1
- AATMOSMXZAZQEV-UHFFFAOYSA-N 2,2,2-trifluoro-n-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical compound C1=CC=C2CC(NC(=O)C(F)(F)F)CC3=C2C1=CC=C3OC AATMOSMXZAZQEV-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical class CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- RLHOXZHHYHCXOY-UHFFFAOYSA-N 2,3-dihydro-1h-phenalen-2-amine Chemical compound C1=CC(CC(N)C2)=C3C2=CC=CC3=C1 RLHOXZHHYHCXOY-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- KQPAOPYTFLPVMQ-UHFFFAOYSA-N 2-(2-methylpropanoylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)C(C)C)C(O)=O)=CC=CC2=C1 KQPAOPYTFLPVMQ-UHFFFAOYSA-N 0.000 description 1
- YOLDGBPANWWZEG-UHFFFAOYSA-N 2-(3-methylbutanoylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CC(C)C)C(O)=O)=CC=CC2=C1 YOLDGBPANWWZEG-UHFFFAOYSA-N 0.000 description 1
- IFCIWTRJYRLWTR-UHFFFAOYSA-N 2-(butanoylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CCC)C(O)=O)=CC=CC2=C1 IFCIWTRJYRLWTR-UHFFFAOYSA-N 0.000 description 1
- IRSWPNROGCRRNG-UHFFFAOYSA-N 2-(chloromethyl)-1-methoxynaphthalene Chemical compound C1=CC=C2C(OC)=C(CCl)C=CC2=C1 IRSWPNROGCRRNG-UHFFFAOYSA-N 0.000 description 1
- BHZUNRHMOGOKFI-UHFFFAOYSA-N 2-(heptanoylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CCCCCC)C(O)=O)=CC=CC2=C1 BHZUNRHMOGOKFI-UHFFFAOYSA-N 0.000 description 1
- XMLFXHMTBCIGBK-UHFFFAOYSA-N 2-(hexanoylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CCCCC)C(O)=O)=CC=CC2=C1 XMLFXHMTBCIGBK-UHFFFAOYSA-N 0.000 description 1
- DBRNEOYVHYLDQG-UHFFFAOYSA-N 2-[(2-bromoacetyl)amino]-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(C(=O)O)NC(=O)CBr)=CC=CC2=C1 DBRNEOYVHYLDQG-UHFFFAOYSA-N 0.000 description 1
- RQIQGMFJILEWTL-UHFFFAOYSA-N 2-[(2-cyclopropylacetyl)amino]-3-naphthalen-1-ylpropanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)CC1CC1 RQIQGMFJILEWTL-UHFFFAOYSA-N 0.000 description 1
- VHPFIXOFIQQEHB-UHFFFAOYSA-N 2-[(2-iodoacetyl)amino]-3-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(CC(C(=O)O)NC(=O)CI)=CC=CC2=C1 VHPFIXOFIQQEHB-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- FGSOKXYAGPLILO-UHFFFAOYSA-N 2-acetamido-3-(1-benzofuran-4-yl)propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=CC=CC2=C1C=CO2 FGSOKXYAGPLILO-UHFFFAOYSA-N 0.000 description 1
- RXRZXDUXCDAULK-UHFFFAOYSA-N 2-acetamido-3-(1-benzothiophen-4-yl)propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=CC=CC2=C1C=CS2 RXRZXDUXCDAULK-UHFFFAOYSA-N 0.000 description 1
- UOSBQOVBBZQTTK-UHFFFAOYSA-N 2-acetamido-3-(1h-indol-4-yl)propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=CC=CC2=C1C=CN2 UOSBQOVBBZQTTK-UHFFFAOYSA-N 0.000 description 1
- KXXKHAYBEJYRII-UHFFFAOYSA-N 2-acetamido-3-(2,7-dimethoxynaphthalen-1-yl)propanoic acid Chemical compound C1=CC(OC)=C(CC(NC(C)=O)C(O)=O)C2=CC(OC)=CC=C21 KXXKHAYBEJYRII-UHFFFAOYSA-N 0.000 description 1
- YGVGKSHYVWCGND-UHFFFAOYSA-N 2-acetamido-3-(5-bromo-1-benzofuran-4-yl)propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=C(Br)C=CC2=C1C=CO2 YGVGKSHYVWCGND-UHFFFAOYSA-N 0.000 description 1
- NAWRZJABPMQVFX-UHFFFAOYSA-N 2-acetamido-3-(5-bromo-1-benzothiophen-4-yl)propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=C(Br)C=CC2=C1C=CS2 NAWRZJABPMQVFX-UHFFFAOYSA-N 0.000 description 1
- LETSWZWNHQIISP-UHFFFAOYSA-N 2-acetamido-3-(5-ethyl-1-benzofuran-4-yl)propanoic acid Chemical compound CCC1=CC=C2OC=CC2=C1CC(NC(C)=O)C(O)=O LETSWZWNHQIISP-UHFFFAOYSA-N 0.000 description 1
- HYGYLNWGXQUFKS-UHFFFAOYSA-N 2-acetamido-3-(5-ethyl-1-benzothiophen-4-yl)propanoic acid Chemical compound CCC1=CC=C2SC=CC2=C1CC(NC(C)=O)C(O)=O HYGYLNWGXQUFKS-UHFFFAOYSA-N 0.000 description 1
- FEDPSEYJRRTXPK-UHFFFAOYSA-N 2-acetamido-3-(5-methoxy-1-benzofuran-4-yl)propanoic acid Chemical compound COC1=CC=C2OC=CC2=C1CC(NC(C)=O)C(O)=O FEDPSEYJRRTXPK-UHFFFAOYSA-N 0.000 description 1
- LDONMJIDZGZAFG-UHFFFAOYSA-N 2-acetamido-3-(5-methoxy-1-benzothiophen-4-yl)propanoic acid Chemical compound COC1=CC=C2SC=CC2=C1CC(NC(C)=O)C(O)=O LDONMJIDZGZAFG-UHFFFAOYSA-N 0.000 description 1
- MYKLEYVLJYINLL-UHFFFAOYSA-N 2-acetamido-3-(5-methoxy-1h-indol-4-yl)propanoic acid Chemical compound COC1=CC=C2NC=CC2=C1CC(NC(C)=O)C(O)=O MYKLEYVLJYINLL-UHFFFAOYSA-N 0.000 description 1
- DABGRZRWEIRTSA-UHFFFAOYSA-N 2-acetamido-3-methoxy-3-oxopropanoic acid Chemical compound COC(=O)C(C(O)=O)NC(C)=O DABGRZRWEIRTSA-UHFFFAOYSA-N 0.000 description 1
- DJEVXRVISVWTKJ-UHFFFAOYSA-N 2-bromo-n-(2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical compound C1=CC(CC(NC(=O)CBr)C2)=C3C2=CC=CC3=C1 DJEVXRVISVWTKJ-UHFFFAOYSA-N 0.000 description 1
- JBSLANHIBKBQGE-UHFFFAOYSA-N 2-cyclopropylacetamide Chemical compound NC(=O)CC1CC1 JBSLANHIBKBQGE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FGQHCAWNAWGBOV-UHFFFAOYSA-N 3-naphthalen-1-yl-2-(pentanoylamino)propanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CCCC)C(O)=O)=CC=CC2=C1 FGQHCAWNAWGBOV-UHFFFAOYSA-N 0.000 description 1
- PQVGZRWNNXJXTJ-UHFFFAOYSA-N 3-naphthalen-1-yl-2-(propanoylamino)propanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)CC)C(O)=O)=CC=CC2=C1 PQVGZRWNNXJXTJ-UHFFFAOYSA-N 0.000 description 1
- NHTUXTBQFBBWDQ-UHFFFAOYSA-N 3-naphthalen-1-yl-2-[(2,2,2-trifluoroacetyl)amino]propanoic acid Chemical compound C1=CC=C2C(CC(C(=O)O)NC(=O)C(F)(F)F)=CC=CC2=C1 NHTUXTBQFBBWDQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KIPKRALHPBZIOD-UHFFFAOYSA-N N-(2,3-dihydro-1H-phenalen-2-yl)-N-methylpropanamide Chemical compound C1=CC(CC(N(C)C(=O)CC)C2)=C3C2=CC=CC3=C1 KIPKRALHPBZIOD-UHFFFAOYSA-N 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- ZUKOPTKRGVDGBG-UHFFFAOYSA-N N-ethyl-N-(4-methyl-2,3-dihydro-1H-phenalen-2-yl)acetamide Chemical compound C1=C(C)C(CC(N(CC)C(C)=O)C2)=C3C2=CC=CC3=C1 ZUKOPTKRGVDGBG-UHFFFAOYSA-N 0.000 description 1
- HIANYINCBJHMAF-UHFFFAOYSA-N N-ethyl-N-(4-methyl-2,3-dihydro-1H-phenalen-2-yl)propanamide Chemical compound C1=C(C)C(CC(N(CC)C(=O)CC)C2)=C3C2=CC=CC3=C1 HIANYINCBJHMAF-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- UTCMYCAFVUUNBK-UHFFFAOYSA-N benzo[cd]indole Chemical compound C1=CC(C=N2)=C3C2=CC=CC3=C1 UTCMYCAFVUUNBK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- 230000027046 diestrus Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IUVAUFLINCLXPK-UHFFFAOYSA-N methyl 1-methoxy-2h-naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)(OC)CC=CC2=C1 IUVAUFLINCLXPK-UHFFFAOYSA-N 0.000 description 1
- MPLSAOVNAXJHHI-UHFFFAOYSA-N methyl 3-methoxynaphthalene-2-carboxylate Chemical compound C1=CC=C2C=C(OC)C(C(=O)OC)=CC2=C1 MPLSAOVNAXJHHI-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- PURITTXNCHNYEP-UHFFFAOYSA-N mukoenine a Chemical compound N1C2=CC=CC=C2C2=C1C(CC=C(C)C)=C(O)C(C)=C2 PURITTXNCHNYEP-UHFFFAOYSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- AEVBTJHNMIBLSQ-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)-2,2,2-trifluoroacetamide Chemical compound C1=CC(CC(NC(=O)C(F)(F)F)C2)=C3C2=CC=CC3=C1 AEVBTJHNMIBLSQ-UHFFFAOYSA-N 0.000 description 1
- PZUQGWJANJHXCP-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)-2-methylpropanamide Chemical compound C1=CC(CC(NC(=O)C(C)C)C2)=C3C2=CC=CC3=C1 PZUQGWJANJHXCP-UHFFFAOYSA-N 0.000 description 1
- JAULYBGDOWVLRL-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)-2-phenylacetamide Chemical compound C1C(C=23)=CC=CC3=CC=CC=2CC1NC(=O)CC1=CC=CC=C1 JAULYBGDOWVLRL-UHFFFAOYSA-N 0.000 description 1
- DZSIAZSRUNTHID-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)-3-methylbutanamide Chemical compound C1=CC(CC(NC(=O)CC(C)C)C2)=C3C2=CC=CC3=C1 DZSIAZSRUNTHID-UHFFFAOYSA-N 0.000 description 1
- JZAUJDKIJGXSBI-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)benzamide Chemical compound C1C(C=23)=CC=CC3=CC=CC=2CC1NC(=O)C1=CC=CC=C1 JZAUJDKIJGXSBI-UHFFFAOYSA-N 0.000 description 1
- SMTBRDJRNVTPBP-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)butanamide Chemical compound C1=CC(CC(NC(=O)CCC)C2)=C3C2=CC=CC3=C1 SMTBRDJRNVTPBP-UHFFFAOYSA-N 0.000 description 1
- BVTDPHFPRSTXTB-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)cyclobutanecarboxamide Chemical compound C1C(C=23)=CC=CC3=CC=CC=2CC1NC(=O)C1CCC1 BVTDPHFPRSTXTB-UHFFFAOYSA-N 0.000 description 1
- PXAKACVXCIWCAH-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)cyclopropanecarboxamide Chemical compound C1C(C=23)=CC=CC3=CC=CC=2CC1NC(=O)C1CC1 PXAKACVXCIWCAH-UHFFFAOYSA-N 0.000 description 1
- PDYYLNJZTACDII-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)heptanamide Chemical compound C1=CC(CC(NC(=O)CCCCCC)C2)=C3C2=CC=CC3=C1 PDYYLNJZTACDII-UHFFFAOYSA-N 0.000 description 1
- OXJLPWUSKMEUEF-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)hexanamide Chemical compound C1=CC(CC(NC(=O)CCCCC)C2)=C3C2=CC=CC3=C1 OXJLPWUSKMEUEF-UHFFFAOYSA-N 0.000 description 1
- NVFCAYUUMVMKHP-UHFFFAOYSA-N n-(2,3-dihydro-1h-phenalen-2-yl)pentanamide Chemical compound C1=CC(CC(NC(=O)CCCC)C2)=C3C2=CC=CC3=C1 NVFCAYUUMVMKHP-UHFFFAOYSA-N 0.000 description 1
- LXLVAVDQWCOCAN-UHFFFAOYSA-N n-(4,9-dimethoxy-2,3-dihydro-1h-phenalen-2-yl)cyclopropanecarboxamide Chemical compound C1C(=C23)C(OC)=CC=C2C=CC(OC)=C3CC1NC(=O)C1CC1 LXLVAVDQWCOCAN-UHFFFAOYSA-N 0.000 description 1
- VACDSJVGBDBTKZ-UHFFFAOYSA-N n-(4,9-dimethoxy-2,3-dihydro-1h-phenalen-2-yl)propanamide Chemical compound C1=C(OC)C(CC(NC(=O)CC)C2)=C3C2=C(OC)C=CC3=C1 VACDSJVGBDBTKZ-UHFFFAOYSA-N 0.000 description 1
- PGEIFJSUNAGDGK-UHFFFAOYSA-N n-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)-2-methylpropanamide Chemical compound C1=CC=C2CC(NC(=O)C(C)C)CC3=C2C1=CC=C3OC PGEIFJSUNAGDGK-UHFFFAOYSA-N 0.000 description 1
- GABNMWDOWMVWMQ-UHFFFAOYSA-N n-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)hexanamide Chemical compound C1=C(OC)C(CC(NC(=O)CCCCC)C2)=C3C2=CC=CC3=C1 GABNMWDOWMVWMQ-UHFFFAOYSA-N 0.000 description 1
- AFVZJQYIPSPCKZ-UHFFFAOYSA-N n-(4-methoxy-2,3-dihydro-1h-phenalen-2-yl)propanamide Chemical compound C1=C(OC)C(CC(NC(=O)CC)C2)=C3C2=CC=CC3=C1 AFVZJQYIPSPCKZ-UHFFFAOYSA-N 0.000 description 1
- KPUXQWUFFVQZKQ-UHFFFAOYSA-N n-(4-methyl-2,3-dihydro-1h-phenalen-2-yl)acetamide Chemical compound C1=C(C)C(CC(NC(=O)C)C2)=C3C2=CC=CC3=C1 KPUXQWUFFVQZKQ-UHFFFAOYSA-N 0.000 description 1
- JPBVZQLIDNVQQI-UHFFFAOYSA-N n-(5-methoxy-2,3-dihydro-1h-phenalen-2-yl)propanamide Chemical compound COC1=CC(CC(NC(=O)CC)C2)=C3C2=CC=CC3=C1 JPBVZQLIDNVQQI-UHFFFAOYSA-N 0.000 description 1
- JDPRRKSHAILUNZ-UHFFFAOYSA-N n-(9-methoxy-3-oxo-1,2-dihydrophenalen-2-yl)acetamide Chemical compound C1=CC=C2C(=O)C(NC(C)=O)CC3=C2C1=CC=C3OC JDPRRKSHAILUNZ-UHFFFAOYSA-N 0.000 description 1
- NJLMTLVITMZSMQ-UHFFFAOYSA-N n-ethyl-4-methyl-2,3-dihydro-1h-phenalen-2-amine Chemical compound C1=C(C)C(CC(NCC)C2)=C3C2=CC=CC3=C1 NJLMTLVITMZSMQ-UHFFFAOYSA-N 0.000 description 1
- DFQICHCWIIJABH-UHFFFAOYSA-N naphthalene-2,7-diol Chemical compound C1=CC(O)=CC2=CC(O)=CC=C21 DFQICHCWIIJABH-UHFFFAOYSA-N 0.000 description 1
- 150000005209 naphthoic acids Chemical class 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000009013 pigment accumulation Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- ZQZJKHIIQFPZCS-UHFFFAOYSA-N propylurea Chemical compound CCCNC(N)=O ZQZJKHIIQFPZCS-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000007280 thionation reaction Methods 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/28—Phenalenes; Hydrogenated phenalenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9504503A FR2732964B1 (fr) | 1995-04-14 | 1995-04-14 | Nouveaux amides tricycliques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961456D0 NO961456D0 (no) | 1996-04-12 |
| NO961456L NO961456L (no) | 1996-10-15 |
| NO309032B1 true NO309032B1 (no) | 2000-12-04 |
Family
ID=9478126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961456A NO309032B1 (no) | 1995-04-14 | 1996-04-12 | Nye tricykliske amider, fremgangsmÕter ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5712312A (es) |
| EP (1) | EP0737670B1 (es) |
| JP (1) | JPH08291121A (es) |
| CN (1) | CN1064349C (es) |
| AT (1) | ATE182325T1 (es) |
| AU (1) | AU704261B2 (es) |
| CA (1) | CA2174034C (es) |
| DE (1) | DE69603309T2 (es) |
| DK (1) | DK0737670T3 (es) |
| ES (1) | ES2136947T3 (es) |
| FR (1) | FR2732964B1 (es) |
| GR (1) | GR3030880T3 (es) |
| NO (1) | NO309032B1 (es) |
| NZ (1) | NZ286359A (es) |
| ZA (1) | ZA962938B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW430660B (en) * | 1996-05-30 | 2001-04-21 | Mochida Pharm Co Ltd | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them |
| IT1304595B1 (it) * | 1997-08-29 | 2001-03-19 | Giorgio Endrici | Inibitore della 5-lipoossigenasi |
| FR2773798B1 (fr) | 1998-01-16 | 2001-02-02 | Adir | Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2001009117A1 (en) * | 1999-07-29 | 2001-02-08 | Allellix Neuroscience Inc. | Tricyclic compounds as glycine transport inhibitors |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| JP4636525B2 (ja) * | 2004-03-12 | 2011-02-23 | 塩野義製薬株式会社 | トランス−４−アミノ−１−シクロヘキサンカルボン酸エチルエステルの塩およびその製造方法 |
| SI3448859T1 (sl) | 2017-03-20 | 2020-02-28 | Forma Therapeutics, Inc. | Sestavki pirolopirola kot aktivatorji piruvat kinaze (PKR) |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3732299A (en) * | 1969-11-03 | 1973-05-08 | Squibb & Sons Inc | Acenaphthene carboxamides |
| NL8003141A (nl) * | 1980-05-30 | 1982-01-04 | Akzo Nv | Biologisch aktieve tricyclische aminen. |
| FR2522658A1 (fr) * | 1982-03-05 | 1983-09-09 | Roussel Uclaf | Application a titre de medicaments de derives du trans 4-amino benz (c,d) indol-5-ol ainsi que de leurs sels, compositions les renfermant, nouveaux derives et leur procede de preparation |
| IL74222A (en) * | 1984-02-06 | 1988-07-31 | Lilly Co Eli | 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them |
| CA1266482A1 (en) * | 1984-05-24 | 1990-03-06 | Carl Kaiser | 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines |
| EP0234113A1 (en) * | 1985-12-31 | 1987-09-02 | The Upjohn Company | 2,3-Dihydro-1H-phenalene-2-amino compounds as anti-psychotic drugs |
| JPS63154660A (ja) * | 1986-12-16 | 1988-06-27 | Kissei Pharmaceut Co Ltd | １，３，４，５−テトラヒドロベンズ〔ｃｄ〕インド−ル誘導体 |
| US5071875A (en) * | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| US5302612A (en) * | 1990-02-26 | 1994-04-12 | Eli Lilly And Company | 6-substituted-hexahydrobenz[cd]indoles |
| US5244911A (en) * | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof |
| US5244912A (en) * | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
| GB9407919D0 (en) * | 1994-04-21 | 1994-06-15 | Glaxo Group Ltd | Chemical compounds |
-
1995
- 1995-04-14 FR FR9504503A patent/FR2732964B1/fr not_active Expired - Fee Related
-
1996
- 1996-04-11 DE DE69603309T patent/DE69603309T2/de not_active Expired - Fee Related
- 1996-04-11 ES ES96400777T patent/ES2136947T3/es not_active Expired - Lifetime
- 1996-04-11 AT AT96400777T patent/ATE182325T1/de not_active IP Right Cessation
- 1996-04-11 DK DK96400777T patent/DK0737670T3/da active
- 1996-04-11 EP EP96400777A patent/EP0737670B1/fr not_active Expired - Lifetime
- 1996-04-12 NO NO961456A patent/NO309032B1/no not_active IP Right Cessation
- 1996-04-12 CA CA002174034A patent/CA2174034C/fr not_active Expired - Fee Related
- 1996-04-12 AU AU50628/96A patent/AU704261B2/en not_active Ceased
- 1996-04-12 NZ NZ286359A patent/NZ286359A/en unknown
- 1996-04-12 CN CN96105003A patent/CN1064349C/zh not_active Expired - Fee Related
- 1996-04-12 US US08/631,196 patent/US5712312A/en not_active Expired - Fee Related
- 1996-04-12 JP JP8091127A patent/JPH08291121A/ja active Pending
- 1996-04-12 ZA ZA962938A patent/ZA962938B/xx unknown
-
1997
- 1997-10-01 US US08/942,177 patent/US5849781A/en not_active Expired - Fee Related
-
1999
- 1999-07-30 GR GR990401961T patent/GR3030880T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3030880T3 (en) | 1999-11-30 |
| CN1139666A (zh) | 1997-01-08 |
| NO961456L (no) | 1996-10-15 |
| AU704261B2 (en) | 1999-04-15 |
| DK0737670T3 (da) | 2000-03-20 |
| CA2174034C (fr) | 2001-01-02 |
| AU5062896A (en) | 1996-10-24 |
| DE69603309T2 (de) | 2000-02-10 |
| EP0737670A1 (fr) | 1996-10-16 |
| DE69603309D1 (de) | 1999-08-26 |
| ATE182325T1 (de) | 1999-08-15 |
| US5712312A (en) | 1998-01-27 |
| JPH08291121A (ja) | 1996-11-05 |
| NO961456D0 (no) | 1996-04-12 |
| ZA962938B (en) | 1996-10-17 |
| ES2136947T3 (es) | 1999-12-01 |
| FR2732964B1 (fr) | 1997-05-16 |
| CA2174034A1 (fr) | 1996-10-15 |
| CN1064349C (zh) | 2001-04-11 |
| NZ286359A (en) | 1997-10-24 |
| FR2732964A1 (fr) | 1996-10-18 |
| EP0737670B1 (fr) | 1999-07-21 |
| US5849781A (en) | 1998-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU703948B2 (en) | New aryl(alkyl)propylamides, process for preparing them and pharmaceutical compositions containing them | |
| KR20080003263A (ko) | 나프탈렌 화합물, 이를 제조하는 방법 및 이를 함유하는약제 조성물 | |
| AU704023B2 (en) | New alkoxyaryl compounds, their processes of preparation and the pharmaceutical compositions which contain them | |
| US5843986A (en) | Tricyclic amide compounds | |
| JP3776608B2 (ja) | 新規なナフタレン化合物、それらの製造方法、及びそれらを含む医薬組成物 | |
| US5780512A (en) | Alkylated (hetero) cyclic compounds | |
| NO309032B1 (no) | Nye tricykliske amider, fremgangsmÕter ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem | |
| MXPA05000033A (es) | Utilizacion de carboxamida de heteroareno como ligandos de dopamina-d3 para el tratamiento de enfermedades de cns. | |
| AU755115B2 (en) | New cyclic compounds having a cycloalkylene chain, a process for their preparation and pharmaceutical compositions containing them | |
| AU703998B2 (en) | New arylalkyl(thio)carboxamides, processes for preparing them and pharmaceutical compositions containing them | |
| KR100912163B1 (ko) | 나프탈렌 화합물, 이를 제조하는 방법 및 이를 함유하는약제 조성물 | |
| JPH10298178A (ja) | 新規複素環化合物、その製造方法、およびそれを含有する医薬組成物 | |
| AU688965B2 (en) | New O-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | |
| JP4015546B2 (ja) | 置換ビフェニル誘導体、その製造方法およびそれを含有する医薬組成物 | |
| WO1998052554A1 (en) | Spirocyclopropyl fluorenes as melatonergic agents | |
| AU644493B2 (en) | Therapeutically useful 2-aminotetralin derivatives | |
| UA80580C2 (en) | Phenylnaphtaline derivatives, method of their obtaining and pharmaceutical composition that comprises them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |